Status:

RECRUITING

Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA

Lead Sponsor:

University of Sao Paulo General Hospital

Conditions:

Obstructive Sleep Apnea

Insomnia

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA...

Detailed Description

The comorbidity between OSA and insomnia (COMISA) is common. COMISA leads to additive impairment of quality of sleep and quality of life compared to patients with insomnia or OSA alone. Patients with ...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of Insomnia;
  • Moderate or severe OSA (AHI ≥ 15 events/h), diagnosed by polysomnography.

Exclusion

  • Craniofacial anatomical abnormalities or severe otorhinolaryngological disorders that potentially impair CPAP use;
  • Use of hypnotics for more than 7 days in the last 2 months;
  • Renal dysfunction (serum creatinine \>2mg/dL);
  • Severe liver or cardiac dysfunction;
  • Alcoholism;
  • Previous CPAP or mandibular advancement device for OSA treatment in the last 12 months.

Key Trial Info

Start Date :

August 24 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 20 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06017921

Start Date

August 24 2023

End Date

December 20 2025

Last Update

March 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sleep Laboratory, Heart Institute, Pulmonary Division, Hospital das Clínicas da Universidade de São Paulo

São Paulo, Brazil, 55

Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA | DecenTrialz